Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1261249/000110465918063591/a18-37096_18k.htm
January 2023
January 2023
November 2022
October 2022
August 2022
August 2022
August 2022
July 2022
July 2022
July 2022
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1261249/000110465918063591/a18-37096_18k.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Agile Therapeutics Inc.
Agile Therapeutics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Agile Therapeutics Inc provided additional information to their SEC Filing as exhibits
Ticker: AGRXEvents:
CIK: 1261249
Form Type: 8-K Corporate News
Accession Number: 0001104659-18-063591
Submitted to the SEC: Wed Oct 24 2018 8:13:30 AM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations